bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S7 from A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
Authors: Shaikh Fyza Y. , White James R. , Gills Joell J. , Hakozaki Taiki , Richard Corentin , Routy Bertrand , Okuma Yusuke , Usyk Mykhaylo , Pandey Abhishek , Weber Jeffrey S. , Ahn Jiyoung , Lipson Evan J. , Naidoo Jarushka , Pardoll Drew M. , Sears Cynthia L.
Published: April 2023

Figure S7. 16S rRNA amplicon data processing for predicted functional elements using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) based on taxonomic composition.
Figure S2 from A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
Authors: Shaikh Fyza Y. , White James R. , Gills Joell J. , Hakozaki Taiki , Richard Corentin , Routy Bertrand , Okuma Yusuke , Usyk Mykhaylo , Pandey Abhishek , Weber Jeffrey S. , Ahn Jiyoung , Lipson Evan J. , Naidoo Jarushka , Pardoll Drew M. , Sears Cynthia L.
Published: April 2023

Figure S2. Alpha diversity analysis across all cohorts using Chao1, observed species, Shannon, and Simpson Reciprocal measures.
Figure S1 from A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
Authors: Shaikh Fyza Y. , White James R. , Gills Joell J. , Hakozaki Taiki , Richard Corentin , Routy Bertrand , Okuma Yusuke , Usyk Mykhaylo , Pandey Abhishek , Weber Jeffrey S. , Ahn Jiyoung , Lipson Evan J. , Naidoo Jarushka , Pardoll Drew M. , Sears Cynthia L.
Published: April 2023

Figure S1. Correlation analysis between 16S rRNA amplicon and metagenomic taxonomic relative abundance estimates.
Figure S1 from Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification
Authors: Lindgaard Sidsel C. , Sztupinszki Zsófia , Maag Emil , Chen Inna M. , Johansen Astrid Z. , Jensen Benny V. , Bojesen Stig E. , Nielsen Dorte L. , Hansen Carsten P. , Hasselby Jane P. , Nielsen Kaspar R. , Szallasi Zoltan , Johansen Julia S.
Published: April 2023

Supplementary figure S1 shows ROC curves for pancreatic ductal adenocarcinoma (PDAC) vs. healthy and PDAC vs. non-malignant pancreatic diseases (chronic pancreatitis, intraductal papillary mucinous neoplasm, and benign pancreatic diseases), a-f: Index I, g-l: Index II
Figure S5 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

Impact of mucin expression on survival outcome in PDAC patients
Supplementary Figure S4 from A MET Targeting Antibody–Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
Authors: Cazes Alex , Betancourt Oscar , Esparza Edgar , Mose Evangeline S. , Jaquish Dawn , Wong Eric , Wascher Alexis A. , Tiriac Hervé , Gymnopoulos Marco , Lowy Andrew M.
Published: April 2023

Post-treatment tumor volumes of PDX1342 grafted tumors
Supplementary Tables from KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
Authors: Jones Gregory D. , Caso Raul , Tan Kay See , Mastrogiacomo Brooke , Sanchez-Vega Francisco , Liu Yuan , Connolly James G. , Murciano-Goroff Yonina R. , Bott Matthew J. , Adusumilli Prasad S. , Molena Daniela , Rocco Gaetano , Rusch Valerie W. , Sihag Smita , Misale Sandra , Yaeger Rona , Drilon Alexander , Arbour Kathryn C. , Riely Gregory J. , Rosen Neal , Lito Piro , Zhang Haiying , Lyden David C. , Rudin Charles M. , Jones David R. , Li Bob T. , Isbell James M.
Published: April 2023

Supplementary Tables
Supplemental Figure 4 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Authors: Stewart Caitlin M. , Michaud Laure , Whiting Karissa , Nakajima Reiko , Nichols Chelsea , De Frank Stephanie , Hamlin Paul A. , Matasar Matthew J. , Gerecitano John F. , Drullinsky Pamela , Hamilton Audrey , Straus David , Horwitz Steven M. , Kumar Anita , Moskowitz Craig H. , Moskowitz Alison , Zelenetz Andrew D. , Rademaker Jurgen , Salles Gilles , Seshan Venkatraman , Schöder Heiko , Younes Anas , Tsui Dana W.Y. , Batlevi Connie Lee
Published: April 2023

Supplemental Figure S4. Progression-free survival Kaplan-Meier curves based on PET and ctDNA parameters. A. PFS based on baseline SUV categorized into lower and higher than median. B. PFS based on baseline tumor glycolysis level lower or higher than median. C. PFS based on baseline metabolic tumor volume (MTV) lower or higher than median.
Supplementary Figure 2 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
Authors: Zhao Shulin , Nicolle Rémy , Augustin Jérémy , Svrcek Magali , de Mestier Louis , Le Corre Delphine , Pietrasz Daniel , Caliez Olivier , Cros Jérôme , Laurent-Puig Pierre , Bachet Jean-Baptiste
Published: April 2023

(A-B) Overall survival curve of three prognostic groups in the training cohort (Cohort Mono N=149) and the validation cohort (Cohort Multi, N=205, 5 patients in the Cohort Multi without enough clinicopathological data were excluded). (A) Training cohort. (B) Validation cohort.
Supplementary Table 2 from Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Authors: Maura Francesco , Diamond Benjamin , Maclachlan Kylee H. , Derkach Andriy , Yellapantula Venkata D. , Rustad Even H. , Hultcrantz Malin , Shah Urvi A. , Hong Jessica , Landau Heather J. , Iacobuzio-Donahue Christine A. , Papaemmanuil Elli , Irby Shani , Crowley Laura , Crane Michael , Webber Mayris P. , Goldfarb David G. , Zeig-Owens Rachel , Giricz Orsi , Verma Amit , Prezant David J. , Dogan Ahmet , Shah Sohrab P. , Zhang Yanming , Landgren Ola
Published: April 2023

Supplementary Table 2. Mutational signature profiles for 5 environmental agents detected in the WTC debris (Kucab et al, Cell 2019).
Supplementary Data from Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy
Authors: Peng Shihong , Hu Pan , Xiao Yu-Tian , Lu Weiqiang , Guo Dandan , Hu Shixiu , Xie Jiayi , Wang Minna , Yu Weiwei , Yang Junjie , Chen Huang , Zhang Xiaomin , Zhu Yasheng , Wang Ye , Yang Yue , Zhu Guanghui , Chen Sujun , Wang Jian , Zhang Bo , Chen Weidong , Wu Huangan , Sun Zhenliang , Ding Tao , Zhang Hankun , Yi Zhengfang , Liu Mingyao , Ren Shancheng
Published: April 2023

Supplementary methods, figure legends and tables
Supplementary Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Authors: Kuemmel Sherko , Campone Mario , Loirat Delphine , Lopez Rafael Lopez , Beck J. Thaddeus , De Laurentiis Michelino , Im Seock-Ah , Kim Sung-Bae , Kwong Ava , Steger Guenther G. , Adelantado Esther Zamora , Duhoux Francois P. , Greil Richard , Kuter Irene , Lu Yen-Shen , Tibau Ariadna , Özgüroğlu Mustafa , Scholz Christian W. , Singer Christian F. , Vega Estela , Wimberger Pauline , Zamagni Claudio , Couillebault Xuan-Mai , Fan Liqiong , Guerreiro Nelson , Mataraza Jennifer , Sand-Dejmek Janna , Chan Arlene
Published: April 2023

Supplementary data
Supplementary Figure from Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial
Authors: Cohen Ezra E.W. , Nabell Lisle , Wong Deborah J. , Day Terry , Daniels Gregory A. , Milhem Mohammed , Deva Sanjeev , Jameson Michael , Guntinas-Lichius Orlando , Almubarak Mohammed , Strother Matthew , Whitman Eric , Chisamore Michael , Obiozor Cynthia , Bagulho Teresa , Gomez-Romo Jose , Guiducci Cristiana , Janssen Robert , Gamelin Erick , Algazi Alain P.
Published: April 2023

Supplementary Figure from Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial
Supplementary Figure S6 from Development and Validation of Machine Learning–based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts
Authors: Chen Kezhong , Nie Yuntao , Park Samina , Zhang Kai , Zhang Yangming , Liu Yuan , Hui Bengang , Zhou Lixin , Wang Xun , Qi Qingyi , Li Hao , Kang Guannan , Huang Yuqing , Chen Yingtai , Liu Jiabao , Cui Jian , Li Mingru , Park In Kyu , Kang Chang Hyun , Shen Haifeng , Yang Yingshun , Guan Tian , Zhang Yaxiao , Yang Fan , Kim Young Tae , Wang Jun
Published: April 2023

Illustration of the CADx product (RX)
Supplementary Figure S5 from Development and Validation of Machine Learning–based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts
Authors: Chen Kezhong , Nie Yuntao , Park Samina , Zhang Kai , Zhang Yangming , Liu Yuan , Hui Bengang , Zhou Lixin , Wang Xun , Qi Qingyi , Li Hao , Kang Guannan , Huang Yuqing , Chen Yingtai , Liu Jiabao , Cui Jian , Li Mingru , Park In Kyu , Kang Chang Hyun , Shen Haifeng , Yang Yingshun , Guan Tian , Zhang Yaxiao , Yang Fan , Kim Young Tae , Wang Jun
Published: April 2023

The generalizability of PKU-M model in prediction of SPNs
Table S10 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Table S10
Shared ratio between primary and metastatic tumors of breast cancer, colorectal cancer, and non-small cell lung cancer.
Figure S7 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Figure S7
Upregulation of PI3K and HIF-1 signaling pathways in SCLC cell lines resistant to cisplatin but sensitive to multiple PI3K inhibitors compared to cell lines sensitive cisplatin but resistant to PI3K inhibitors by gene set enrichment analysis (GSEA).
Figure S2 from Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer
Authors: Jin Ying , Chen Yamei , Tang Huarong , Hu Xiao , Hubert Shawna M. , Li Qian , Su Dan , Xu Haimiao , Fan Yun , Yu Xinmin , Chen Qixun , Liu Jinshi , Hong Wei , Xu Yujin , Deng Huan , Zhu Dapeng , Li Pansong , Gong Yuhua , Xia Xuefeng , Gay Carl M. , Zhang Jianjun , Chen Ming
Published: April 2023

Figure S2
The ratio of each type of nucleotide substitution. For each patient, the stacked bar on the left represents treatment-naÃ¯ve and the bar on the right represents post-treatment.
Supplementary Figure Legends from Whole-body PET Imaging of T-cell Response to Glioblastoma
Authors: Nobashi Tomomi W. , Mayer Aaron T. , Xiao Zunyu , Chan Carmel T. , Chaney Aisling M. , James Michelle L. , Gambhir Sanjiv S.
Published: April 2023

Supplemental Figure legends
Supplementary Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Chiappori Alberto A. , Creelan Ben , Tanvetyanon Tawee , Gray Jhanelle E. , Haura Eric B. , Thapa Ram , Barlow Margaret L. , Chen Zhihua , Chen Dung Tsa , Beg Amer A. , Boyle Theresa A. , Castro Julio , Morgan Liza , Morris Erick , Aregay Mehreteab , Hurtado Felipe K. , Manenti Luigi , Antonia Scott
Published: April 2023

Supplementary Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Table S1 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

Patients' database
Figure S9 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

The levels of ctDNA of 15 HGS-EOC patients are shown in relation to the patient's clinical history. The TF% in cfDNA is reported for each plasma sample (purple line) withdrawn against the CA-125 levels (green line). Red bars refer to the tumor volume calculated from TC analysis as described in Supplementary methods (). * indicates patients for whom TC scan is not available at time of diagnosis and/or at recurrence. Figures S11 and S12 specifically show cases where the TF% in cfDNA does not anticipate tumor progression.
Figure S6 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

A Distribution of the percentage of CNI and TF (y axis) in patients' plasma, stratified on their response to front-line Pt based chemotherapy. Horizontal lines within each box represent the median values, while whiskers are estimated as 1.5 times the standard deviations. B Spaghetti plots of TF values across time windows (X axis) separately for therapy response and therapy type. C Spaghetti plots of CNI values across time windows (X axis) divided for therapy response and therapy type.
Supplementary Data from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Authors: Dmello Crismita , Sonabend Aarón , Arrieta Victor A. , Zhang Daniel Y. , Kanojia Deepak , Chen Li , Gould Andrew , Zhang Jiangshan , Kang Seong Jae , Winter Jan , Horbinski Craig , Amidei Christina , Győrffy Balázs , Cordero Alex , Chang Catalina Lee , Castro Brandyn , Hsu Patrick , Ahmed Atique U. , Lesniak Maciej S. , Stupp Roger , Sonabend Adam M.
Published: April 2023

Supplementary Data from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Figure S3 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

Copy number profiles comparison between the ctDNA and tDNA at time of diagnosis. For a representative case (patient 21580) the genome-wide patterns of SCNA was plotted for plasma (PL-1) and matched tumor tissues samples (A, B, C). Individual dots represent bins, whereas horizontal white lines indicate segments, covering bins of expected equal copy number. The x-axis and y-axis represent the loci of 23 chromosomes and corresponding copy numbers, in Log2 scale, respectively. The Pearson's correlation index between copy number profiles measured in the plasma and in each matched tumor biopsies is reported on the left side of the picture. The TF and CNI values are reported on the right side below each biopsy. Gray boxes highlight the two regions of focal amplification on chromosome 3 and 8. Copy number gains are represented in red; copy number losses, blue TF, tumor fraction. CNI, copy number instability. r, Pearson's correlation. p, p-value.
Figure S2 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

Heatmap of SCNA profiles of tumor tissues and plasma. Genome-wide patterns distribution of SCNA in plasma (PL-1) and matched tumor tissues from 35 patients at diagnosis (T0). X- axis depicts the loci of the 23 chromosomes, while y-axis indicates the copy number calls for each sample, grouped by patient. Copy number gains are represented in red; copy number losses, blue. Gray, neutral. White cells are the centromeres of each chromosome. The name of each plasma samples is shown in red on the left side of the figure.
Figure S12 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

The levels of ctDNA of 15 HGS-EOC patients are shown in relation to the patient's clinical history. The TF% in cfDNA is reported for each plasma sample (purple line) withdrawn against the CA-125 levels (green line). Red bars refer to the tumor volume calculated from TC analysis as described in Supplementary methods (). * indicates patients for whom TC scan is not available at time of diagnosis and/or at recurrence. Figures S11 and S12 specifically show cases where the TF% in cfDNA does not anticipate tumor progression.
Figure S1 from Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Authors: Paracchini Lara , Beltrame Luca , Grassi Tommaso , Inglesi Alessia , Fruscio Robert , Landoni Fabio , Ippolito Davide , Delle Marchette Martina , Paderno Mariachiara , Adorni Marco , Jaconi Marta , Romualdi Chiara , D'Incalci Maurizio , Siravegna Giulia , Marchini Sergio
Published: April 2023

Consort Diagram. The flow diagram depicts how the total 46 HGS-EOC cases were retrospectively selected in this study to generate genome wide somatic copy number profiles using shallow whole genome sequencing analysis.
Supplementary Methods from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
Authors: Wang Xian , Veeraraghavan Jamunarani , Liu Chia-Chia , Cao Xixi , Qin Lanfang , Kim Jin-Ah , Tan Ying , Loo Suet Kee , Hu Yiheng , Lin Ling , Lee Sanghoon , Shea Martin J. , Mitchell Tamika , Li Shunqiang , Ellis Matthew J. , Hilsenbeck Susan G. , Schiff Rachel , Wang Xiao-Song
Published: April 2023

Supplementary Methods
Supplementary Table from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Authors: Lee Jung-Min , Moore Richard G. , Ghamande Sharad , Park Min S. , Diaz John P. , Chapman Julia , Kendrick James , Slomovitz Brian M. , Tewari Krishnansu S. , Lowe Elizabeth S. , Milenkova Tsveta , Kumar Sanjeev , Dymond Mike , Brown Jessica , Liu Joyce F.
Published: April 2023

Supplementary Table from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Supplementary Figure from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Authors: Lee Jung-Min , Moore Richard G. , Ghamande Sharad , Park Min S. , Diaz John P. , Chapman Julia , Kendrick James , Slomovitz Brian M. , Tewari Krishnansu S. , Lowe Elizabeth S. , Milenkova Tsveta , Kumar Sanjeev , Dymond Mike , Brown Jessica , Liu Joyce F.
Published: April 2023

Supplementary Figure from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Supplementary Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Authors: Bilen Mehmet A. , Rini Brian I. , Voss Martin H. , Larkin James , Haanen John B.A.G. , Albiges Laurence , Pagliaro Lance C. , Voog Eric G. , Lam Elaine T. , Kislov Nikolay , McGregor Bradley A. , Lalani Aly-Khan A. , Huang Bo , di Pietro Alessandra , Krulewicz Stan , Robbins Paul B. , Choueiri Toni K.
Published: April 2023

Supplementary Data from Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Supplementary Data from Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
Authors: Skwarski Michael , McGowan Daniel R. , Belcher Elizabeth , Di Chiara Francesco , Stavroulias Dionisios , McCole Mark , Derham Jennifer L. , Chu Kwun-Ye , Teoh Eugene , Chauhan Jagat , O’Reilly Dawn , Harris Benjamin H.L. , Macklin Philip S. , Bull Joshua A. , Green Marcus , Rodriguez-Berriguete Gonzalo , Prevo Remko , Folkes Lisa K. , Campo Leticia , Ferencz Petra , Croal Paula L. , Flight Helen , Qi Cathy , Holmes Jane , O’Connor James P.B. , Gleeson Fergus V. , McKenna W. Gillies , Harris Adrian L. , Bulte Daniel , Buffa Francesca M. , Macpherson Ruth E. , Higgins Geoff S.
Published: April 2023

Trial Protocol
Supplementary Table from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Authors: Shi Zhen , Wulfkuhle Julia , Nowicka Malgorzata , Gallagher Rosa I. , Saura Cristina , Nuciforo Paolo G. , Calvo Isabel , Andersen Jay , Passos-Coelho José Luis , Gil-Gil Miguel J. , Bermejo Begoña , Pratt Debra A. , Ciruelos Eva M. , Villagrasa Patricia , Wongchenko Matthew J. , Petricoin Emanuel F. , Oliveira Mafalda , Isakoff Steven J.
Published: April 2023

Supplementary Table from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Table S3 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Table S3
Supplementary figure 1 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

Tumor somatic alterations defined by targeted capture sequencing. (A)Using this capture probe panel, we obtained an average of 8,121,723 sequencing reads per tumor (range: 3,068,132 - 13,084,648), which corresponded to a minimum coverage of >1000x per base targeted in all samples as detailed in Supplemental Table 1. Somatic alteration analysis identified an average of 4.1 mutations and INDELs per tumor (range 0 - 28, of 226 genes tested)). As shown in the oncoplot, while several commonly altered HNSCC genes were identified, we also observed several interesting mutations in DNA damage repair proteins, including three mutations in ATM (R2419G, G1023E and a splice region alteration), ATRX (L532F), BRCA1 (stopgain) and BRCA2 (frameshift alteration). Four of 5 patients harboring these mutations experienced tumor progression. (B) The level of microhomology (in bp) at the breakpoint is numerically depicted. Number of overlapping nucleotides between HPV and host (indicating microhomology) are indicated as positive numbers, 0 indicates a clean break between HPV and host with no overlapping or inserted sequence, and negative numbers indicate the number of inserted base pairs between the HPV and host genome.
Supplementary fig 2 from A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas
Authors: Yu Shengnan , Wei Shiyou , Savani Milan , Lin Xiang , Du Kuang , Mender Ilgen , Siteni Silvia , Vasilopoulos Themistoklis , Reitman Zachary J. , Ku Yin , Wu Di , Liu Hao , Tian Meng , Chen Yaohui , Labrie Marilyne , Charbonneau Casey M. , Sugarman Eric , Bowie Michelle , Hariharan Seethalakshmi , Waitkus Matthew , Jiang Wen , McLendon Roger E. , Pan Edward , Khasraw Mustafa , Walsh Kyle M. , Lu Yiling , Herlyn Meenhard , Mills Gordon , Herbig Utz , Wei Zhi , Keir Stephen T. , Flaherty Keith , Liu Lunxu , Wu Kongming , Shay Jerry W. , Abdullah Kalil , Zhang Gao , Ashley David M.
Published: April 2023

Supplementary Figure 1. (A-B) Successful labeling of CellTrace Violet for M059K and H4 cells. M059K and H4 cells were labeled with a cell membrane dye CellTrace Violet and verified the success of labeling by FACS. (C-D) Cell viability of M059K and H4 following THIO treatment. M059K and H4 cells were treated with control medium or THIO at 5µM and then determined the cell viability percentage via detecting PSVue643 and PI by FACS. (E-F) Western blot results of time-course and dose-titration experiments in M059K and H4. For the time-course experiment, cells were treated with THIO at 5µM and proteins were tested at 0, 24, 48 and 72 hours. For dose-titration experiments, cells were treated with serious doses of THIO for 72 hours. TMZ functions as control. Actin serves as a loading control. Supplementary Figure 2. (A) Crystal violet staining images for acquired TMZ-resistant (TR) cell lines after treatment. (B) The heatmap of quantification results of the crystal violet images of TR cells. % relative to control. (C) Senescence assay for DBTRG-05MG, M059K and H4 cells following THIO treatment at 1 µM for 7 days, and then fixed and stained using Senescence β-Galactosidase Staining Kit and taken images by microscope. (D-F) Quantification results of senescence assay for DBTRG-05MG, M059K and H4 cells. 7 fields were counted for each group. (G-J) Neurosphere growth curves for T98G, U87MG, 13.0302 and TS-603 treated with or without THIO at 5 µM.
Supplementary Figure from Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Authors: Palmer Adam C. , Izar Benjamin , Hwangbo Haeun , Sorger Peter K.
Published: April 2023

Supplementary Figure from Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Supplementary Figure S7 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

OV-Q1, OV-αCD47-G1 and OV-αCD47-G4 treatments increase immune cell infiltration in the ID8-hCD47 immunocompetent ovarian cancer metastasis mouse model.
Supplementary Figure S3 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

The effect of αCD47-G1 or αCD47-G4 on the expression of NK cell markers.
Supplementary Figure S10 from Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer
Authors: Tian Lei , Xu Bo , Teng Kun-Yu , Song Mihae , Zhu Zheng , Chen Yuqing , Wang Jing , Zhang Jianying , Feng Mingye , Kaur Balveen , Rodriguez Lorna , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

OV-Q1, OV-αmCD47-G2b and OV-αmCD47-G3 treatments increase immune cell infiltration in the ID8 immunocompetent ovarian cancer metastasis mouse model.
Supplemental Table S4 from Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial
Authors: Edlund Karolina , Madjar Katrin , Lebrecht Antje , Aktas Bahriye , Pilch Henryk , Hoffmann Gerald , Hofmann Manfred , Kolberg Hans-Christian , Boehm Daniel , Battista Marco , Seehase Martina , Stewen Kathrin , Gebhard Susanne , Cadenas Cristina , Marchan Rosemarie , Brenner Walburgis , Hasenburg Annette , Koelbl Heinz , Solbach Christine , Gehrmann Mathias , Tanner Berno , Weber Karsten E. , Loibl Sibylle , Sachinidis Agapios , Rahnenführer Jörg , Schmidt Marcus , Hengstler Jan G.
Published: April 2023

Genes with a significantly lower expression in patients predicted to not achieve a pCR with an extremely low predicted probability of pCR (a) and enes with a significantly higher expression in patients predicted to not achieve a pCR with an extremely low predicted probability of pCR.
Supplementary Figure Legend from A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)
Authors: Flaig Thomas W. , Tangen Catherine M. , Daneshmand Siamak , Alva Ajjai , Lerner Seth P. , Lucia M. Scott , McConkey David J. , Theodorescu Dan , Goldkorn Amir , Milowsky Matthew I. , Bangs Rick , MacVicar Gary R. , Bastos Bruno R. , Fowles Jared S. , Gustafson Daniel L. , Plets Melissa , Thompson Ian M.
Published: April 2023

Supplementary Figure Legend
Supp Figure 3 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Authors: Mooi Jennifer , Chionh Fiona , Savas Peter , Da Gama Duarte Jessica , Chong Geoffrey , Brown Stephen , Wong Rachel , Price Timothy J. , Wann Alysson , Skrinos Effie , Mariadason John M. , Tebbutt Niall C.
Published: April 2023

Supplementary Fig 3. Hierarchical clustering of plasma antibody profiles after 6 weeks of study treatment, using the Spearman rank correlation method with average linkage. Patient ID (0n) at the 6-week time point (best tumour response, PFS).
Supp Figure 2 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Authors: Mooi Jennifer , Chionh Fiona , Savas Peter , Da Gama Duarte Jessica , Chong Geoffrey , Brown Stephen , Wong Rachel , Price Timothy J. , Wann Alysson , Skrinos Effie , Mariadason John M. , Tebbutt Niall C.
Published: April 2023

Supplementary Fig 2. Change in overall (A) and specific (B) plasma antibody titres against tumour antigens from baseline (D0) to 6 weeks of treatment (6W), n=8 patients.
Supp Figure 1 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Authors: Mooi Jennifer , Chionh Fiona , Savas Peter , Da Gama Duarte Jessica , Chong Geoffrey , Brown Stephen , Wong Rachel , Price Timothy J. , Wann Alysson , Skrinos Effie , Mariadason John M. , Tebbutt Niall C.
Published: April 2023

Supplementary Fig 1. (A) PFS in plasma VEGF-C subgroups, (B) OS in plasma Ang-2 subgroups.
Supplementary Figure from Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy
Authors: Guix Ines , Liu Qi , Pujana Miquel Angel , Ha Patrick , Piulats Josep , Linares Isabel , Guedea Ferran , Mao Jian-Hua , Lazar Ann , Chapman Jocelyn , Yom Sue S. , Ashworth Alan , Barcellos-Hoff Mary Helen
Published: April 2023

Supplementary Figure from Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy
Figure S6 from TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Authors: Kawazoe Akihito , Itahashi Kota , Yamamoto Noboru , Kotani Daisuke , Kuboki Yasutoshi , Taniguchi Hiroya , Harano Kenichi , Naito Yoichi , Suzuki Mitsuko , Fukutani Miki , Higuchi Tsukiko , Ikeno Takashi , Wakabayashi Masashi , Sato Akihiro , Koyama Shohei , Nishikawa Hiroyoshi , Shitara Kohei
Published: April 2023

Figure S6
Supplementary Data from Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
Authors: Biswas Tithi , Dowlati Afshin , Kunos Charles A. , Pink John J. , Oleinick Nancy L. , Malik Shakun , Fu Pingfu , Cao Shufen , Bruno Debora S. , Bajor David L. , Patel Monaliben , Gerson Stanton L. , Machtay Mitchell
Published: April 2023

Supplementary Data from Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
Supplementary Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Authors: Yu Alice L. , Gilman Andrew L. , Ozkaynak M. Fevzi , Naranjo Arlene , Diccianni Mitchell B. , Gan Jacek , Hank Jacquelyn A. , Batova Ayse , London Wendy B. , Tenney Sheena C. , Smith Malcolm , Shulkin Barry L. , Parisi Marguerite , Matthay Katherine K. , Cohn Susan L. , Maris John M. , Bagatell Rochelle , Park Julie R. , Sondel Paul M.
Published: April 2023

Figure S1a
Supplementary Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Authors: Yu Alice L. , Gilman Andrew L. , Ozkaynak M. Fevzi , Naranjo Arlene , Diccianni Mitchell B. , Gan Jacek , Hank Jacquelyn A. , Batova Ayse , London Wendy B. , Tenney Sheena C. , Smith Malcolm , Shulkin Barry L. , Parisi Marguerite , Matthay Katherine K. , Cohn Susan L. , Maris John M. , Bagatell Rochelle , Park Julie R. , Sondel Paul M.
Published: April 2023

Figure S1b
Appendix from TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Authors: Kawazoe Akihito , Itahashi Kota , Yamamoto Noboru , Kotani Daisuke , Kuboki Yasutoshi , Taniguchi Hiroya , Harano Kenichi , Naito Yoichi , Suzuki Mitsuko , Fukutani Miki , Higuchi Tsukiko , Ikeno Takashi , Wakabayashi Masashi , Sato Akihiro , Koyama Shohei , Nishikawa Hiroyoshi , Shitara Kohei
Published: April 2023

Appendix
Supplementary Tables from G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Authors: Kelly Gregory M. , Al-Ejeh Fares , McCuaig Robert , Casciello Francesco , Ahmad Kamal Nabilah , Ferguson Blake , Pritchard Antonia L. , Ali Sayed , Silva Ines P. , Wilmott James S. , Long Georgina V. , Scolyer Richard A. , Rao Sudha , Hayward Nicholas K. , Gannon Frank , Lee Jason S.
Published: April 2023

Supplementary Tables
Supplementary Figure from Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
Authors: Cruz-Duarte Raquel , Rebelo de Almeida Cátia , Negrão Magda , Fernandes Afonso , Borralho Paula , Sobral Daniel , Gallego-Paez Lina M. , Machado Daniel , Gramaça João , Vílchez José , Xavier Ana T. , Ferreira Miguel Godinho , Miranda Ana R. , Mansinho Helder , Brito Maria J. , Pacheco Teresa R. , Abreu Catarina , Lucia-Costa Ana , Mansinho André , Fior Rita , Costa Luís , Martins Marta
Published: April 2023

Supplementary Figure from Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
Supplementary Data from Facts and Hopes in Immunotherapy of Endometrial Cancer
Authors: Marín-Jiménez Juan A. , García-Mulero Sandra , Matías-Guiu Xavier , Piulats Josep M.
Published: April 2023

Supplementary Data from Facts and Hopes in Immunotherapy of Endometrial Cancer
Supplementary Data from Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
Authors: Cruz-Duarte Raquel , Rebelo de Almeida Cátia , Negrão Magda , Fernandes Afonso , Borralho Paula , Sobral Daniel , Gallego-Paez Lina M. , Machado Daniel , Gramaça João , Vílchez José , Xavier Ana T. , Ferreira Miguel Godinho , Miranda Ana R. , Mansinho Helder , Brito Maria J. , Pacheco Teresa R. , Abreu Catarina , Lucia-Costa Ana , Mansinho André , Fior Rita , Costa Luís , Martins Marta
Published: April 2023

Supplementary Data from Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
Table S2 from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Table S2
Figure S6 from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Figure S6
Supplementary Figures from An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission
Authors: Biavati Luca , Huff Carol Ann , Ferguson Anna , Sidorski Amy , Stevens M. Amanda , Rudraraju Lakshmi , Zucchinetti Cristina , Ali Syed Abbas , Imus Philip , Gocke Christian B. , Gittelman Rachel M. , Johnson Sarah , Sanders Catherine , Vignali Marissa , Gandhi Anita , Ye Xiaobu , Noonan Kimberly A. , Borrello Ivan
Published: April 2023

Supplementary Figures
Figure S3 from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Figure S3
Figure S1 from Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
Authors: Telli Melinda L. , Nagata Hiroshi , Wapnir Irene , Acharya Chaitanya R. , Zablotsky Kaitlin , Fox Bernard A. , Bifulco Carlo B. , Jensen Shawn M. , Ballesteros-Merino Carmen , Le Mai Hope , Pierce Robert H. , Browning Erica , Hermiz Reneta , Svenson Lauren , Bannavong Donna , Jaffe Kim , Sell Jendy , Foerter Kellie Malloy , Canton David A. , Twitty Christopher G. , Osada Takuya , Lyerly H. Kim , Crosby Erika J.
Published: April 2023

Figure S1
Supplementary Table 7 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Authors: Even Caroline , Wang Hung-Ming , Li Shau-Hsuan , Ngan Roger K-C , Dechaphunkul Arunee , Zhang Li , Yen Chia-Jui , Chan Po Chung , Chakrabandhu Somvilai , Ma Brigette B.Y. , Tanasanvimon Suebpong , Lee Victor H.F. , Lou Pei-Jen , Li Zujun , Spira Alexander I. , Sukari Ammar , Guigay Joël , McCune Steven , Gonzalez-Maffe Juan , Szpakowski Sebastian , Yao Yao , Liang Hongzi , Mataraza Jennifer , Séchaud Romain , Manenti Luigi , Lim Darren W-T.
Published: April 2023

Supplemental Table S7. Primary PK parameters for spartalizumab
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Authors: Grossman Joseph E. , Muthuswamy Lakshmi , Huang Ling , Akshinthala Dipikaa , Perea Sofia , Gonzalez Raul S. , Tsai Leo L. , Cohen Jonah , Bockorny Bruno , Bullock Andrea J. , Schlechter Benjamin , Peters Mary Linton B. , Conahan Catherine , Narasimhan Supraja , Lim Christine , Davis Roger B. , Besaw Robert , Sawhney Mandeep S. , Pleskow Douglas , Berzin Tyler M. , Smith Martin , Kent Tara S. , Callery Mark , Muthuswamy Senthil K. , Hidalgo Manuel
Published: April 2023

Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Supplementary Table 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Authors: Even Caroline , Wang Hung-Ming , Li Shau-Hsuan , Ngan Roger K-C , Dechaphunkul Arunee , Zhang Li , Yen Chia-Jui , Chan Po Chung , Chakrabandhu Somvilai , Ma Brigette B.Y. , Tanasanvimon Suebpong , Lee Victor H.F. , Lou Pei-Jen , Li Zujun , Spira Alexander I. , Sukari Ammar , Guigay Joël , McCune Steven , Gonzalez-Maffe Juan , Szpakowski Sebastian , Yao Yao , Liang Hongzi , Mataraza Jennifer , Séchaud Romain , Manenti Luigi , Lim Darren W-T.
Published: April 2023

Supplemental Table S2. Chemotherapy regimens given to patients in the chemotherapy arm
Supplementary Figure 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Authors: Even Caroline , Wang Hung-Ming , Li Shau-Hsuan , Ngan Roger K-C , Dechaphunkul Arunee , Zhang Li , Yen Chia-Jui , Chan Po Chung , Chakrabandhu Somvilai , Ma Brigette B.Y. , Tanasanvimon Suebpong , Lee Victor H.F. , Lou Pei-Jen , Li Zujun , Spira Alexander I. , Sukari Ammar , Guigay Joël , McCune Steven , Gonzalez-Maffe Juan , Szpakowski Sebastian , Yao Yao , Liang Hongzi , Mataraza Jennifer , Séchaud Romain , Manenti Luigi , Lim Darren W-T.
Published: April 2023

Supplemental Figure S2. Adverse events in crossover group
Supplementary Figure 1 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Authors: Even Caroline , Wang Hung-Ming , Li Shau-Hsuan , Ngan Roger K-C , Dechaphunkul Arunee , Zhang Li , Yen Chia-Jui , Chan Po Chung , Chakrabandhu Somvilai , Ma Brigette B.Y. , Tanasanvimon Suebpong , Lee Victor H.F. , Lou Pei-Jen , Li Zujun , Spira Alexander I. , Sukari Ammar , Guigay Joël , McCune Steven , Gonzalez-Maffe Juan , Szpakowski Sebastian , Yao Yao , Liang Hongzi , Mataraza Jennifer , Séchaud Romain , Manenti Luigi , Lim Darren W-T.
Published: April 2023

Supplemental Figure S1. CONSORT diagram
Supplementary Data from Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas
Authors: Wo Jennifer Y. , Clark Jeffrey W. , Eyler Christine E. , Mino-Kenudson Mari , Klempner Samuel J. , Allen Jill N. , Keane Florence K. , Parikh Aparna R. , Roeland Eric , Drapek Lorraine C. , Ryan David P. , Corcoran Ryan B. , Van Seventer Emily , Fetter Isobel J. , Shahzade Heather A. , Khandekar Melin J. , Lanuti Michael , Morse Christopher R. , Heist Rebecca S. , Ulysse Christine A. , Christopher Benjamin , Baglini Christian , Yeap Beow Y. , Mullen John T. , Hong Theodore S.
Published: April 2023

Supplemental Appendix 1 Full Protocol
Supplementary Data from Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas
Authors: Wo Jennifer Y. , Clark Jeffrey W. , Eyler Christine E. , Mino-Kenudson Mari , Klempner Samuel J. , Allen Jill N. , Keane Florence K. , Parikh Aparna R. , Roeland Eric , Drapek Lorraine C. , Ryan David P. , Corcoran Ryan B. , Van Seventer Emily , Fetter Isobel J. , Shahzade Heather A. , Khandekar Melin J. , Lanuti Michael , Morse Christopher R. , Heist Rebecca S. , Ulysse Christine A. , Christopher Benjamin , Baglini Christian , Yeap Beow Y. , Mullen John T. , Hong Theodore S.
Published: April 2023

Supplemental Appendix 3: Normal RT Dose Constraints.
Supplementary Data from The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
Authors: Manca Paolo , Corallo Salvatore , Busico Adele , Lonardi Sara , Corti Francesca , Antoniotti Carlotta , Procaccio Letizia , Clavarezza Matteo , Smiroldo Valeria , Tomasello Gianluca , Murialdo Roberto , Sartore-Bianchi Andrea , Racca Patrizia , Pagani Filippo , Randon Giovanni , Martinetti Antonia , Sottotetti Elisa , Palermo Federica , Perrone Federica , Tamborini Elena , Prisciandaro Michele , Raimondi Alessandra , Di Bartolomeo Maria , Morano Federica , Pietrantonio Filippo
Published: April 2023

Suppl Fig 2
Supplementary Data from The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
Authors: Manca Paolo , Corallo Salvatore , Busico Adele , Lonardi Sara , Corti Francesca , Antoniotti Carlotta , Procaccio Letizia , Clavarezza Matteo , Smiroldo Valeria , Tomasello Gianluca , Murialdo Roberto , Sartore-Bianchi Andrea , Racca Patrizia , Pagani Filippo , Randon Giovanni , Martinetti Antonia , Sottotetti Elisa , Palermo Federica , Perrone Federica , Tamborini Elena , Prisciandaro Michele , Raimondi Alessandra , Di Bartolomeo Maria , Morano Federica , Pietrantonio Filippo
Published: April 2023

Suppl Fig 3